Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
$71.67
$1.48(2.88%)
At close: 4:00 PM EST
$71.67
$1.48(2.88%)
Day’s Range― - ―
52-Week Range$47.50 - $79.50
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.09M
Market Cap
$8.52B
Enterprise Value$9.78B
Total Cash (Recent Filing)$701.96M
Total Debt (Recent Filing)$1.51B
Price to Earnings (P/E)15.1
Beta0.40
Next Earnings
Feb 24, 2026EPS Estimate
1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.72
Shares Outstanding117,597,000
10 Day Avg. Volume1,986,153
30 Day Avg. Volume2,089,081
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)16.67
Price to Sales (P/S)5.97
P/FCF Ratio12.95
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue7.87
Enterprise Value/Gross Profit9.31
Enterprise Value/Ebitda11.03
Forecast
1Y Price Target
$78.00Price Target Upside8.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business DevelopmentAnalyst notes repeated business-development wins broaden ENHANZE's partner base and strengthen the platform's relevance, creating multiple streams of potential royalty income.
High-value Immunology PartnershipTakeda's license to develop a subcutaneous version of an established gastrointestinal therapy using ENHANZE anchors the platform in a high-volume immunology market and could secure a durable royalty opportunity.
Strategic Acquisition And Technology ExpansionThe acquisition of Elektrofi and its Hypercon formulation technology expands capability to enable ultra-high concentration, lower-volume injections and could materially expand the range of drugs suitable for at-home administration.
Bears Say
Deal Transparency And Revenue VisibilityUndisclosed upfront and milestone amounts create uncertainty around near-term revenue visibility and make it harder for analysts to forecast cash flow from new partnerships.
Execution And Clinical RiskCommercial uptake of ENHANZE remains uncertain given the potential for unfavorable clinical results, dependence on large collaborators, and risk of dilution, any of which could limit royalty growth.
Royalty Economics And ExclusivityA lower-than-historical royalty rate on recent deals, combined with shorter expected exclusivity, could reduce per-product revenue and pressure long-term royalty baselines.
Halozyme News
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $47.50 and its highest was $79.50 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $8.52B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Feb 24, 2026 which is in 40 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Nov 03, 2025. The company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 1.9.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 117,597,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.72 in its last earnings report, beating expectations of $1.63. Following the earnings report the stock price went up 2.795%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.00 (8.83% Upside)
$78.00 (8.83% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 603.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.37%
12-Months-Change
Fundamentals
Return on Equity
124.50%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
HALO Company Deck
HALO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call revealed strong financial performance driven by robust revenue growth from key subcutaneous therapies and strategic acquisitions. However, there are some challenges with collaboration revenue declines and pending acquisitions. Overall, the positive aspects significantly outweigh the negatives.View all HALO earnings summariesHALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
HALO Stock 12 Month Forecast
Average Price Target
$78.00
▲(8.83% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Bio-Techne
―
Moderna
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---